Validated Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry Method for the Determination of Pramipexole in Human Plasma

被引:20
作者
Yadav, Manish [1 ,2 ]
Rao, Rajasekhar [2 ]
Kurani, Hemal [2 ]
Rathod, Jaysukh [2 ]
Patel, Rakesh [2 ]
Singhal, Puran [2 ]
Shrivastav, Pranav S. [1 ]
机构
[1] Gujarat Univ, Sch Sci, Dept Chem, Ahmadabad 380009, Gujarat, India
[2] Veeda Clin Res, Bioanalyt Res Dept, Ahmadabad 3800015, Gujarat, India
关键词
EXPERIMENTAL-DESIGN; PARKINSONS-DISEASE; DIHYDROCHLORIDE; IONIZATION; U-98,528; URINE; MS/MS;
D O I
10.1093/chromsci/48.10.811
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A sensitive and high throughput ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS-MS) method has been developed for the determination of pramipexole, a dopamine agonist, in human plasma. Sample preparation involved liquid-liquid extraction of pramipexole and ranitidine as the internal standard (IS) in ethyl acetate from 100 μL human plasma. The chromatographic separation is achieved on a Waters Acquity UPLC BEH C18 (100 mm x 2.1 mm, 1.7 μm) analytical column using an isocratic mobile phase, consisting of 10 mM ammonium formate (pH 7.50)-acetonitrile ( 15:85, v/v), at a flow-rate of 0.5 mL/min. The precursor → product ion transition for pramipexole (m/z 212.1 → 153.0) and IS (m/z 315.0 → 176.1) were monitored on a triple quadrupole mass spectrometer, operating in the multiple reaction monitoring (MRM) and positive ion mode. The method was validated over a wide dynamic concentration range of 20-4020 pg/mL. Matrix effect is assessed by post-column infusion experiment and the process efficiency were 91.9% and 85.7% for pramipexole and IS, respectively. The method is rugged and rapid with a total run time of 1.5 min and is applied to a bioequivalence study of 0.25 mg PPX tablet formulation in 30 healthy Indian male subjects under fasting condition.
引用
收藏
页码:811 / 818
页数:8
相关论文
共 21 条
  • [1] Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of pramipexole in human plasma: application to a clinical pharmacokinetic study
    Bharathi, D. Vijaya
    Hotha, Kishore Kumar
    Sagar, P. V. Vidya
    Kumar, S. Sirish
    Naidu, A.
    Mullangi, Ramesh
    [J]. BIOMEDICAL CHROMATOGRAPHY, 2009, 23 (02) : 212 - 218
  • [2] Biglan Kevin M, 2002, Expert Opin Pharmacother, V3, P197, DOI 10.1517/14656566.3.2.197
  • [3] The role of UHPLC in pharmaceutical development
    Chesnut, Stephen M.
    Salisbury, John J.
    [J]. JOURNAL OF SEPARATION SCIENCE, 2007, 30 (08) : 1183 - 1190
  • [4] Constantinescu Radu, 2008, Neuropsychiatr Dis Treat, V4, P337
  • [5] Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-L-propylamino-benzathiazole dihydrochloride]
    Danzeisen, R
    Schwalenstoecker, B
    Gillardon, F
    Buerger, E
    Krzykalla, V
    Klinder, K
    Schild, L
    Hengerer, B
    Ludolph, AC
    Dorner-Ciossek, C
    Kussmaul, L
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 316 (01) : 189 - 199
  • [6] Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease
    Deleu, D
    Northway, MG
    Hanssens, Y
    [J]. CLINICAL PHARMACOKINETICS, 2002, 41 (04) : 261 - 309
  • [7] Jancic B, 2007, ACTA CHIM SLOV, V54, P49
  • [8] Lau YY, 1996, J CHROMATOGR B, V683, P209
  • [9] Lau YY, 1996, J CHROMATOGR B, V683, P217
  • [10] Pramipexole and Parkinson's disease, an update
    Martinez-Corral, M.
    Kulisevsky, J.
    [J]. REVISTA DE NEUROLOGIA, 2008, 46 (01) : 49 - 52